ONCOLOGY IMAGING

NEW FRONTIERS

The revolution in personalized healthcare has prompted the growth and development of technologies that span all disciplines of science and medicine. Nowhere do we see this more at play than in oncology. Fusing personalized medicine with new therapeutics, imaging and biomarker development has helped lead us into an advanced realm of healthcare delivery.

To realize the full potential of these exciting new technologies, it is critical to precisely and accurately measure their effects. Every data point counts – from pre-clinical through FDA submission – because each one provides the critical information you need to complete your clinical trial with confidence. That is why Imaging Endpoints is dedicated to providing its sponsors with the most informative imaging methodologies and the operational excellence to help ensure every data point counts. We can help with all aspects of trial planning and administration including protocol development, data collection and management, instrumentation standardization and regulatory compliance. Our client-centered approach and strict attention to regulations ensures the most accurate and timely data possible.

OUR EXPERTISE

Our team of board-certified and fellowship-trained radiologists and nuclear medicine physicians has been successfully involved in the design and completion of all aspects of the core lab pathway, from RFP response to study closure. Our oncology trained radiology specialists, as well as a network of board-certified oncologists are always readily accessible to you as frequently and intensively as required for the success of your clinical trial.

Through our unique RADAR program and deep partnerships with global leaders in cancer biology and imaging, we are able to leverage emerging imaging technologies to assist our clients in uncovering diverse biologic associations using standard non-invasive imaging modalities such as CT, MRI and PET. This enables you to track and monitor a particular targeted therapy at a molecular level, leading to a deeper, richer evaluation, and ultimately a more effective trial design. Our service and technology allow us to provide you with more sophisticated information about your trial, and ultimately your therapy, without affecting data capture workflow.

ASSESSMENTS

Exclusive to Imaging Endpoints

- Radiogenomic analysis and trait(s) pertaining to investigational agent/target pathology

Semi-quantitative

- RECIST (1.0, 1.1)
ONCOLOGY IMAGING (Cont.)

- WHO criteria
- PERCIST criteria for PET response
- EORTC criteria for PET response
- CHOI criteria for response to tumors

Quantitative

- Tumor volume – based on CT, MRI
- Tumor metabolic volume – based on PET/CT
- Tumor density

Functional

- Perfusion measurements (PET, DCE-MRI and CT)
- Metabolic and proliferation (PET/CT – FDG & FLT)
- Tumor Hypoxia (F-MISO)

MODALITIES

- PET/CT – multiple radiopharmaceuticals
- MRI – DCE, ADC, anatomical, spectroscopy
- CT – Perfusion, anatomical
- Breast-based imaging modalities: MRI, digital mammography, ultrasound, tomosynthesis, Positron Emission Mammography (PEM)
- US
- Angiography
- SPECT
- X-ray

TAKE A LOOK AT IMAGING ENDPOINTS

No other imaging core lab can match the experience and expertise of Imaging Endpoints.
Contact us to find out all the ways we can accelerate your clinical trial.